1. High-dose tramadol conversion to buprenorphine-naloxone.
- Author
-
Kirk JK, Boyd CT, Cassidy-Vu L, McRae LP, Strickland HE, and Fagan EB
- Subjects
- Female, Humans, Buprenorphine, Naloxone Drug Combination therapeutic use, Analgesics, Opioid adverse effects, Narcotic Antagonists therapeutic use, Receptors, Opioid, Tramadol adverse effects, Opioid-Related Disorders diagnosis, Opioid-Related Disorders drug therapy, Buprenorphine therapeutic use
- Abstract
Buprenorphine-naloxone is a combination medication of an opioid partial agonist and opioid antagonist that is proven to be effective in outpatient management of opioid use disorder (OUD). Tramadol is a centrally acting analgesic. This commonly used pain medication inhibits serotonin and noradrenaline reuptake by acting as a selective agonist on opioid µ receptors. Transition and tapering high-dose tramadol to buprenorphine-naloxone is not well described in the literature. We report a case of a patient who was taking 1,000-1,250 mg of tramadol daily upon presentation to the clinic. She was originally prescribed 150 mg daily with escalation in dose and frequency over a 10-year period. The patient was converted to bupren-orphine-naloxone and has been successful in treatment of OUD for 1 year.
- Published
- 2023
- Full Text
- View/download PDF